Iterum Therapeutics PLC
ITRMF Healthcare Biotechnology
In the quarter to September 2025, revenue grew 110.8%, EPS grew 33.3% and free cash flow fell 179.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ITRMF
Iterum Therapeutics PLC (ITRMF) EV/Sales
As of 14 October 2026, Iterum Therapeutics PLC (ITRMF) trades at a EV/Sales of 24.4×. Over the past ten years it has ranged from −64.6× (December 2022) to 468× (June 2021); the current reading is higher than 41% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2019 | 103× | — |
| FY2018 | −30.7× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2025 | 57.7× | (30.83%) |
| Mar 2019 | 83.4× | — |
| Dec 2018 | −30.7× | — |
| Sep 2018 | 1.7× | — |
| 3 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SILO Silo Pharma, Inc. compare | −54.6× |
| CARM Carisma Therapeutics Inc. compare | 0.0× |
| NEXI NexImmune, Inc. compare | n/m |
| GNPX GENPREX compare | n/m |
| ARTL Artelo Biosciences, Inc. compare | n/m |
| ABPO Abpro Holdings Inc. compare | n/m |
| MLEC Moolec Science SA compare | 0.1× |
| ITRMF Iterum Therapeutics PLC | 24.4× |
| TRVN Trevena, Inc. compare | 35.0× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)